Related Experiment Video
Updated: May 25, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Sphingosine 1-phosphate signalling in cancer
Nigel J Pyne1, Francesca Tonelli, Keng Gat Lim
1Cell Biology Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK. n.j.pyne@strath.ac.uk
Biochemical Society Transactions
|January 21, 2012
Summary
Sphingosine 1-phosphate (S1P) signaling is crucial in cancer progression, influencing cell migration and drug resistance. Targeting S1P pathways, particularly sphingosine kinase 1 and its receptors, offers potential for novel cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in various cellular processes.
- S1P exerts its functions by binding to G-protein-coupled receptors (S1P1-S1P5) and regulating intracellular targets.
- Dysregulation of S1P signaling is implicated in cancer development and progression.
Purpose of the Study:
- To investigate the correlation between sphingosine kinase 1 (SK1) and S1P receptor expression in tumors and clinical outcomes.
- To elucidate the molecular mechanisms by which SK1 and S1P receptors contribute to cancer cell migration.
- To review the role of SK1 in chemotherapeutic resistance and S1P receptor interactions with oncogenes like HER2.
Main Methods:
- Analysis of SK1 and S1P receptor expression in tumor samples.
- Molecular studies to define mechanisms of cancer cell migration.
- Review of existing literature on S1P signaling in cancer, drug resistance, and therapeutic strategies.
Main Results:
- SK1 and S1P receptor expression correlates with clinical outcomes in cancer patients.
- SK1 and S1P receptors play a significant role in promoting cancer cell migration.
- S1P signaling contributes to chemotherapeutic resistance and interacts with oncogenic pathways.
Conclusions:
- Targeting SK1 and S1P receptors presents a promising therapeutic strategy for cancer treatment.
- Modulating S1P receptor interactions with tyrosine kinases can inhibit cancer progression.
- Further research into small-molecule inhibitors of SK1, including allosteric modulators and those targeting protein degradation, is warranted.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:11IP3/DAG Signaling Pathway
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...